After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
The investigators showed that template-free Cas9 editing is capable of repair to a predicted genotype, allowing for correction of disease-associated mutations.
Scripps Research Translational Institute has teamed with Nvidia to create a center of excellence for AI in genomics and wearable sensors.
At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.
The company aims to commercialize ProstaGene's PCaTest, which uses a 16-gene panel to determine the overall outcome of a patient's prostate cancer.
The company has not released data on its method, but describes a circulating tumor DNA approach that has similarities to what other firms are pursuing.
Some partners are implementing their solutions on the Azure cloud while others will accept output from Microsoft's genomics pipeline as input into their solutions.
With an SBIR Phase II grant in hand, Michigan startup Parabricks is adding both speed and AI to variant calling as it eyes a Series A round next year.
The chatbot developed with Clear Genetics follows up with patients after genetic testing and educates family members at risk for inheriting the same mutations.
The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.